Nyrada Inc. (NYR.AX)
AUD 0.1
(-2.0%)
AUD 0.1
(-2.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | -4.76 Million AUD | -28.6% |
| 2023 | -3.7 Million AUD | 65.71% |
| 2022 | -10.81 Million AUD | 21.34% |
| 2021 | -13.75 Million AUD | -186.24% |
| 2020 | -4.8 Million AUD | -269.87% |
| 2019 | 2.82 Million AUD | 1551.31% |
| 2018 | 171.25 Thousand AUD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 FY | -4.76 Million AUD | -28.6% |
| 2024 Q4 | -4.76 Million AUD | 0.0% |
| 2024 Q2 | -4.64 Million AUD | 0.0% |
| 2023 Q2 | -9.34 Million AUD | 0.0% |
| 2023 FY | -3.7 Million AUD | 65.71% |
| 2023 Q4 | -3.7 Million AUD | 0.0% |
| 2022 Q4 | -10.81 Million AUD | 0.0% |
| 2022 Q2 | -11.1 Million AUD | 0.0% |
| 2022 FY | -10.81 Million AUD | 21.34% |
| 2021 FY | -13.75 Million AUD | -186.24% |
| 2021 Q4 | -13.75 Million AUD | 0.0% |
| 2021 Q2 | -3.71 Million AUD | 0.0% |
| 2020 Q4 | -4.8 Million AUD | 0.0% |
| 2020 FY | -4.8 Million AUD | -269.87% |
| 2020 Q2 | 3.31 Million AUD | 0.0% |
| 2019 FY | 2.82 Million AUD | 1551.31% |
| 2019 Q4 | 4.66 Million AUD | 0.0% |
| 2019 Q1 | - AUD | 0.0% |
| 2018 FY | 171.25 Thousand AUD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| EZZ Life Science Holdings Limited | -18.89 Million AUD | 74.764% |
| Anatara Lifesciences Ltd | -982.1 Thousand AUD | -385.627% |
| Zelira Therapeutics Limited | 5.06 Million AUD | 194.12% |
| Biome Australia Limited | -1.56 Million AUD | -205.18% |
| Patrys Limited | -2.24 Million AUD | -112.856% |
| Orthocell Limited | -19.92 Million AUD | 76.063% |
| Imugene Limited | -91.56 Million AUD | 94.791% |
| Noxopharm Limited | -2.31 Million AUD | -105.583% |
| PYC Therapeutics Limited | -65.76 Million AUD | 92.747% |
| Chimeric Therapeutics Limited | -3.05 Million AUD | -56.219% |
| Prescient Therapeutics Limited | -10.16 Million AUD | 53.07% |
| Proteomics International Laboratories Limited | -6.32 Million AUD | 24.581% |
| Cynata Therapeutics Limited | -6.2 Million AUD | 23.142% |
| CSL Limited | 15.76 Billion AUD | 100.03% |
| Arovella Therapeutics Limited | -12.71 Million AUD | 62.488% |
| Bio-Gene Technology Limited | -709.55 Thousand AUD | -572.161% |
| Clinuvel Pharmaceuticals Limited | -182.98 Million AUD | 97.394% |
| Starpharma Holdings Limited | -19.83 Million AUD | 75.951% |
| Nanollose Limited | -96.22 Thousand AUD | -4856.481% |
| Memphasys Limited | 4.13 Million AUD | 215.331% |
| Invex Therapeutics Ltd | -6.02 Million AUD | 20.841% |
| NeuroScientific Biopharmaceuticals Limited | -4.95 Million AUD | 3.73% |
| Amplia Therapeutics Limited | -1.82 Million AUD | -161.537% |
| Botanix Pharmaceuticals Limited | -79.3 Million AUD | 93.986% |
| Island Pharmaceuticals Limited | -1.23 Million AUD | -285.121% |
| Race Oncology Limited | -17.18 Million AUD | 72.253% |
| Telix Pharmaceuticals Limited | -105.79 Million AUD | 95.492% |
| Dimerix Limited | -21.99 Million AUD | 78.313% |
| PharmAust Limited | -9.71 Million AUD | 50.903% |
| Immutep Limited | -122.18 Million AUD | 96.097% |
| Clarity Pharmaceuticals Ltd | -136.5 Million AUD | 96.506% |
| Alterity Therapeutics Limited | -12.47 Million AUD | 61.783% |
| BTC Health Limited | -2.02 Million AUD | -135.856% |
| Acrux Limited | -1.45 Million AUD | -227.118% |
| Neuren Pharmaceuticals Limited | -17.09 Million AUD | 72.099% |
| Biotron Limited | -386.06 Thousand AUD | -1135.371% |
| Tissue Repair Ltd | -16.44 Million AUD | 70.991% |
| AdAlta Limited | -845.17 Thousand AUD | -464.307% |
| Radiopharm Theranostics Limited | -18.57 Million AUD | 74.324% |
| Hexima Limited | -2.22 Million AUD | -114.237% |
| AnteoTech Limited | -5 Million AUD | 4.642% |
| Paradigm Biopharmaceuticals Limited | -17.58 Million AUD | 72.873% |
| Recce Pharmaceuticals Ltd | -3.39 Million AUD | -40.435% |
| Avecho Biotechnology Limited | -5.32 Million AUD | 10.506% |
| Actinogen Medical Limited | -9.13 Million AUD | 47.771% |
| Immuron Limited | -11.48 Million AUD | 58.469% |
| Argenica Therapeutics Limited | -15.91 Million AUD | 70.028% |